Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
5
×
boston top stories
5
×
clinical trials
life sciences
national blog main
boston
national top stories
san francisco blog main
cancer
cancer drugs
dyne therapeutics
fda
myotonic dystrophy type 1
rare disease drugs
san diego blog main
third rock ventures
ally bridge group
amgen
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
big data analytics
biotech ipos
black diamond therapeutics
blackrock
bladder cancer
bluebird bio
blueprint medicines
casdin capital
cobimetinib
deals
deciphera pharmaceuticals
diabetic nephropathy
duchenne muscular dystrophy
eli lilly
endometral cancer
europe blog main
european society for medical oncology
What
drug
5
×
ipo
5
×
medicines
genetic
therapeutics
biotech
cancer
company
diseases
dyne
lead
million
muscle
new
raised
rare
research
targets
ago
analysis
bio
biotechs
black
bring
brings
clinic
companies
considering
data
despite
develop
developing
diamond
disorders
dyne’s
early
eluded
employing
expected
experimental
Language
unset
Current search:
drug
×
" boston top stories "
×
" boston blog main "
×
ipo
×
@xconomy.com
4 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
4 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic